Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
The Motley Fool October 25, 2006 Brian Lawler	Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool August 1, 2008 Brian Lawler	Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool September 11, 2008 Brian Lawler	ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.
The Motley Fool September 22, 2008 Brian Lawler	Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems.
The Motley Fool January 29, 2007 Brian Lawler	ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool May 29, 2008 Brian Lawler	Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors.
The Motley Fool June 16, 2010 Ryan McBride	Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool June 22, 2011	Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
The Motley Fool March 23, 2005 Stephen D. Simpson	Kerr-McGee Gets the Message Will this deepwater driller, a historical underachiever, succeed in acting in shareholders' best interests?
The Motley Fool October 2, 2008 Brian Orelli	Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal?
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool September 1, 2009 Rick Aristotle Munarriz	Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%.
The Motley Fool April 15, 2005 Tom Taulli	Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger.
The Motley Fool April 16, 2009 Brian Orelli	Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders?
The Motley Fool July 8, 2008 Rick Aristotle Munarriz	Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!.
National Real Estate Investor December 4, 2002 Parke Chapman	Investor now holds 6.9% stake in Insignia Carl Icahn now holds a 6.9% stake in real estate operator Insignia Financial Group Inc.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool June 19, 2008 Brian Orelli	Live From Bio: Activist Investors Activist investors throw a fit and try to get management changes when they're not happy, like Carl Icahn has done with ImClone Systems and tried to do with Biogen Idec. As they become more common, how are companies dealing with them?
The Motley Fool July 22, 2011 Evan Niu	Clorox to Icahn: "It's Not You, It's Me" Clorox announces that its board has unanimously rejected Icahn's unsolicited bid to acquire the company.
The Motley Fool August 1, 2007 Brian Lawler	ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth.
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool April 21, 2005 Timothy M. Otte	Brawling at Blockbuster What's with this war of words between corporate raider Carl Icahn and Blockbuster management?
The Motley Fool December 21, 2010 Toby Shute	Chesapeake Energy in the Crosshairs What's this activist investor got planned for the energy titan?
The Motley Fool April 27, 2007 Brian Lawler	Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note.
The Motley Fool April 30, 2007 Tom Taulli	Proxy Fights 101 How shareholder skirmishes are transforming Wall Street. It's smart to understand how proxy fights work, but don't assume they're a good system for investing. Proxy battles often target struggling companies with volatile stocks.
Search Engine Watch August 6, 2008 Kevin Ryan	Woohoo for Yahoo Even after the vote re-count, a majority of shareholders voted Yahoo's board in, and Carl Icahn settled for the right to propose two board seats and a spot for himself. At the end of the day, what's more important than rebuilding the Web's biggest brand?
The Motley Fool October 12, 2005 W.D. Crotty	Icahn's Case for Time Warner Carl Icahn issues an open letter to shareholders pushing for change on the company's board. Investors should realize, though, that just because Icahn is around, that doesn't mean their shares will automatically go up.
BusinessWeek July 30, 2009	A Trio of Options Shareholders could soon have an easier route to proposing their own directors on company boards, thanks to three changes
InternetNews November 14, 2007 Larry Barrett	BEA to File Past-Due Financial Reports BEA Systems will try to save its Nasdaq listing and protect itself from future proxy fights with shareholders.
The Motley Fool February 12, 2004 Bill Mann	ImClone's Mysterious Plunge Investors flee the stock the instant before it receives great news. Oops.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.